Meredith Cook Sells 250 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $56.82, for a total transaction of $14,205.00. Following the transaction, the vice president now directly owns 56,738 shares in the company, valued at approximately $3,223,853.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Meredith Cook also recently made the following trade(s):

• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $59.62, for a total transaction of $14,905.00.
• On Friday, July 12th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $64.91, for a total value of $16,227.50.

ANI Pharmaceuticals Stock Down 3.9 %

ANIP opened at $56.20 on Tuesday. The company has a current ratio of 3.97, a quick ratio of 3.07 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81. The business has a 50 day moving average of $61.39 and a 200-day moving average of $63.93. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 35.04 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million during the quarter, compared to analysts’ expectations of $129.09 million. During the same quarter in the prior year, the firm posted $1.06 EPS. The company’s revenue for the quarter was up 18.5% on a year-over-year basis. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC boosted its position in shares of ANI Pharmaceuticals by 287.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after acquiring an additional 15,790 shares in the last quarter. Great Lakes Advisors LLC lifted its position in shares of ANI Pharmaceuticals by 67.1% during the 4th quarter. Great Lakes Advisors LLC now owns 48,252 shares of the specialty pharmaceutical company’s stock worth $2,661,000 after buying an additional 19,378 shares during the period. BNP Paribas Financial Markets boosted its stake in ANI Pharmaceuticals by 106.9% in the 1st quarter. BNP Paribas Financial Markets now owns 20,739 shares of the specialty pharmaceutical company’s stock valued at $1,434,000 after buying an additional 10,716 shares in the last quarter. Wakefield Asset Management LLLP acquired a new position in ANI Pharmaceuticals during the first quarter worth $979,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $600,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on ANIP. StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial reiterated a “hold” rating and issued a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.